Baxter International Inc
BAX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$96.00 | Czxnclw | Phnlfszjf |
Baxter Earnings: Mildly Exceeded Cautious Expectations on Improving Hospital Budgets and Trends
Narrow-moat Baxter mildly exceeded expectations in the second quarter, and management provided scenarios for bottom-line results that depend on the timing of the Biopharma Solutions, or BPS, sale and look slightly higher than its previous 2023 outlook. Our near-term estimates look in line with these expectations, and we do not intend to change our $67 fair value estimate. Shares remain undervalued.